Latest Recruitment News

SHAPE Australia has lifted FY27 project wins above $1.4 billion after securing an approximately $800 million DigiCo data centre contract, with the project expected to add about $200 million of revenue in each of FY27 and FY28. The award comes alongside stronger modular revenue, a new Western Australian facility and a quarter-end backlog up 21%.

Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.

Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.

Accordant Group lifted first-half revenue 8% to NZ$88.5 million and cut its net loss to NZ$234,000, while reducing net bank debt by NZ$7 million since March. The staffing group still has a long way to go before returning to profit or restoring dividends.

The Takeovers Panel has ordered the forced sale of a substantial parcel of DGR Global shares after finding undisclosed associations and takeover-law breaches pushed related parties’ voting power as high as 45.43%. The orders also open the way for a takeover bid or scheme while imposing new controls on DGR’s board and major shareholders.

Nova Eye Medical delivered 30% year-on-year sales growth in the September quarter, alongside positive operating cash flow and EBITDA. The company confirmed FY27 guidance, but is still seeking to replace a related-party funding facility carrying 15% interest.

Fleetwood enters FY27 with a stronger Community Solutions business, a $61.5 million net cash position and a plan to restore Building Solutions to profitability in the second half. The key tests are completing the Red Dog Village acquisition and proving its manufacturing reset can overcome a $8.7 million underlying loss.

Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.

Almasar Minerals ended its first post-listing quarter with A$10.24 million in cash and a pipeline of geophysical surveys and auger drilling across its Saudi Arabian licences. The company has yet to report new exploration results, leaving execution and target quality as the next tests for the newly listed explorer.

Actinogen Medical has received an A$10.84 million R&D tax rebate, leaving it with A$21.9 million in pro forma cash and no debt just weeks before its pivotal Alzheimer’s readout. The company says topline XanaMIA results remain due in mid-November.

EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.

Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.